ArticleScientific reports2025
SKP2 protein as a prognostic biomarker for glioma and promotes tumor progression by regulating the cell cycle.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
SKP2 (S-phase kinase-associated protein 2) plays an important role in the regulation of the cell cycle, tumorigenesis, progression, and metastasis. However, its functional role in gliomas is currently unclear. This study aimed to investigate the relationship between SKP2 and the progression of gliomas, and its effects on the glioma cell cycle. The relationship between SKP2 expression levels and clinical characteristics of gliomas was explored in our datasets. Kaplan-Meier analysis and COX regression were conducted to evaluate the prognostic role of SKP2. Differentially expressed genes were identified between high and low SKP2 groups. The function and related mechanisms of SKP2 were evaluated based on Gene Ontology and Gene Set Enrichment Analysis. LASSO-Cox was used to screen the variables, and the prediction model was established by nomogram analysis. The effects of SKP2 on the glioma cell cycle were examined in cellular experiments. The SKP2 expression level was positively correlated with adverse clinical features of gliomas, and overall survival with high SKP2 expression was significantly shortened. Gene enrichment analysis showed that the differential genes in the SKP2 high-expression group were mainly enriched in cell cycle and mitosis. In vitro experiments confirmed that silencing of SKP2 arrested the glioma cell cycle at the G1 phase in both U87 and U251 cells. In conclusion, SKP2 may serve as a potential prognostic biomarker for glioma patients and is associated with poor prognosis. Additionally, SKP2 is closely related to the glioma cell cycle, suggesting that SKP2 may serve as a potential therapeutic target. However, further prospective studies and external cohort validations are needed to confirm its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.